source
- Arvinas and Pfizer license newly approved PROTAC breast cancer drug Veppanu to Rigel PharmaceuticalsArvinas and Pfizer have signed a licensing agreement that transfers ownership of their newly approved breast cancer drug, Veppanu, to San Francisco‑based Rigel Pharmaceuticals. The deal gives Arvi…
- FDA grants breakthrough therapy designation to Emi-Le for advanced adenoid cystic carcinomaThe U.S. Food and Drug Administration has granted breakthrough therapy designation to Emi-Le for patients with locally advanced, recurrent or metastatic adenoid cystic carcinoma (ACC). Phase 1 tri…